AU3961897A - Methods for identifying vasoprotective agents - Google Patents

Methods for identifying vasoprotective agents

Info

Publication number
AU3961897A
AU3961897A AU39618/97A AU3961897A AU3961897A AU 3961897 A AU3961897 A AU 3961897A AU 39618/97 A AU39618/97 A AU 39618/97A AU 3961897 A AU3961897 A AU 3961897A AU 3961897 A AU3961897 A AU 3961897A
Authority
AU
Australia
Prior art keywords
identifying
methods
vasoprotective agents
vasoprotective
agents
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU39618/97A
Other languages
English (en)
Inventor
Richard H. Karas
Michael E. Mendelsohn
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts Medical Center Inc
Original Assignee
New England Medical Center Hospitals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New England Medical Center Hospitals Inc filed Critical New England Medical Center Hospitals Inc
Publication of AU3961897A publication Critical patent/AU3961897A/en
Abandoned legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5061—Muscle cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6897—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids involving reporter genes operably linked to promoters
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5014—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity
    • G01N33/5017—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing toxicity for testing neoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5064—Endothelial cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Food Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Engineering & Computer Science (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
AU39618/97A 1996-07-19 1997-07-21 Methods for identifying vasoprotective agents Abandoned AU3961897A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08684704 1996-07-19
US08/684,704 US5728534A (en) 1996-07-19 1996-07-19 Methods for identifying cardiovascular therapeutic agents
PCT/US1997/012804 WO1998003634A1 (en) 1996-07-19 1997-07-21 Methods for identifying vasoprotective agents

Publications (1)

Publication Number Publication Date
AU3961897A true AU3961897A (en) 1998-02-10

Family

ID=24749216

Family Applications (1)

Application Number Title Priority Date Filing Date
AU39618/97A Abandoned AU3961897A (en) 1996-07-19 1997-07-21 Methods for identifying vasoprotective agents

Country Status (5)

Country Link
US (3) US5728534A (esLanguage)
EP (1) EP0956342A1 (esLanguage)
JP (1) JP2000515376A (esLanguage)
AU (1) AU3961897A (esLanguage)
WO (1) WO1998003634A1 (esLanguage)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1005357A1 (en) * 1997-04-14 2000-06-07 The Regents Of The University Of California Peptide antiestrogen compositions and methods for treating breast cancer
US6670398B2 (en) * 1997-05-14 2003-12-30 Atherogenics, Inc. Compounds and methods for treating transplant rejection
US6852878B2 (en) * 1998-05-14 2005-02-08 Atherogenics, Inc. Thioketals and thioethers for inhibiting the expression of VCAM-1
KR20010020611A (ko) * 1997-07-01 2001-03-15 아테로제닉스, 인코포레이티드 항산화제에 의한 과증식질병 치료의 향상
WO2000061230A2 (en) * 1999-04-09 2000-10-19 Karo Bio Ab Estrogen receptors-beta antagonism and bone diseases
WO2001024826A2 (en) * 1999-10-06 2001-04-12 The Brigham And Women's Hospital, Inc. Inrease of enos activity through activation of the pi3-kinase/akt pathway by estrogens
AU5340101A (en) * 2000-04-11 2001-10-23 Atherogenics Inc Compounds and methods to increase plasma hdl cholesterol levels and improve hdl functionality
WO2001081614A2 (en) * 2000-04-25 2001-11-01 Chemicon International Cell proliferation assay
US7094559B1 (en) * 2000-08-08 2006-08-22 Wyeth Assay to identify estrogen receptor dependent ligands that regulate the hepatic lipase promoter
DE10046647A1 (de) * 2000-09-20 2002-03-28 Ludwig Wildt Verfahren zur Bestimmung der Peptidhormon-Aktivitäten oder der Steroidhormon-Aktivitäten eines Materials oder Stoffgemisches
US20030054332A1 (en) * 2001-05-10 2003-03-20 Barbosa Miguel S. Markers for evaluating estrogenic activity
JP2003180393A (ja) * 2001-12-13 2003-07-02 Otsuka Pharmaceut Co Ltd レポータージーンアッセイ法
DE10233516A1 (de) * 2002-07-23 2004-02-12 Aventis Pharma Deutschland Gmbh Verfahren zur Identifizierung von Substanzen
WO2005003301A2 (en) * 2003-06-17 2005-01-13 Signal Pharmaceuticals, Inc. Methods, compositions, and kits for predicting the effect of compounds on hot flash symptoms
JP5666134B2 (ja) 2007-01-10 2015-02-12 ヘモシアー・リミテッド・ライアビリティ・カンパニーＨｅｍｏＳｈｅａｒ， ＬＬＣ 血管疾患の新たな治療標的を同定するためのインビトロの血行力学的内皮／平滑筋細胞共培養モデルの使用
US20090075888A1 (en) * 2007-09-13 2009-03-19 University Of North Texas Health Science Center At Fort Worth Cardiovascular and Brain Cell Therapy Using Intracellular Ryanodine Receptor Modulation by the Estrogen Receptor Beta
WO2011162115A1 (ja) * 2010-06-21 2011-12-29 国立大学法人東京工業大学 膵臓β細胞増殖因子を利用した医薬組成物
US9658211B2 (en) 2012-04-18 2017-05-23 Hemoshear, Llc In vitro model for pathological or physiologic conditions
US9617521B2 (en) 2013-10-21 2017-04-11 Hemoshear, Llc In vitro model for a tumor microenvironment
EP3893958B1 (en) 2018-12-11 2026-07-29 Revamp Medical Ltd. Systems for adjusting blood flow in a body lumen

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5071773A (en) * 1986-10-24 1991-12-10 The Salk Institute For Biological Studies Hormone receptor-related bioassays
EP0463081B1 (en) * 1989-03-17 1998-05-20 The Salk Institute For Biological Studies Hormone response element compositions and assay
US5580722A (en) * 1989-07-18 1996-12-03 Oncogene Science, Inc. Methods of determining chemicals that modulate transcriptionally expression of genes associated with cardiovascular disease
EP0694078A4 (en) * 1993-04-07 1997-06-25 Ligand Pharm Inc SORTING PROCESS RELATING TO RECEPTOR AGONISTS
US5512483A (en) * 1993-05-21 1996-04-30 Mcgill University Expression vectors responsive to steroid hormones
US5506102A (en) * 1993-10-28 1996-04-09 Ligand Pharmaceuticals Incorporated Methods of using the A form of the progesterone receptor to screen for antagonists of steroid intracellar receptor-mediated transcription
CA2190275A1 (en) * 1994-05-18 1995-11-23 Thomas Hermann Screening for cytokine modulators

Also Published As

Publication number Publication date
EP0956342A1 (en) 1999-11-17
US20030013143A1 (en) 2003-01-16
WO1998003634A1 (en) 1998-01-29
US5728534A (en) 1998-03-17
EP0956342A4 (esLanguage) 1999-11-17
JP2000515376A (ja) 2000-11-21
US6448019B1 (en) 2002-09-10

Similar Documents

Publication Publication Date Title
AU2845197A (en) Cycloalkano-pyridines
AU3556297A (en) Database apparatus
AU2684197A (en) Handleset
AU5579198A (en) Self-tuition apparatus
AU9372498A (en) De-wiring apparatus
AU3497297A (en) Roller-ski apparatus
AU2090897A (en) Hydroxyhexahydropyridazines
AU1733997A (en) Blower-vacuum apparatus
AU3620297A (en) Substituted triazoloazinesulphonamides
AU1337099A (en) Method for identifying micro-organisms
AU2183997A (en) New method
AU3130597A (en) Tristetraprolin
AU3704297A (en) Method
AU3771497A (en) Substituted p-trifluoromethylphenyluracils
AU1926397A (en) Substituted 1-methyl-3-benzyluracils
AU2237197A (en) Fishing-lure
AU3947997A (en) Identification apparatus
AU4604397A (en) (o-acyl-p-n-acylamino-phenyl)-o-phosphoethanolamines
AU1900097A (en) Cremators
AU4415897A (en) Phenolic stain-resists
AUPO870297A0 (en) Method
AUPO937097A0 (en) Method
AU1597197A (en) Thienoquinolines
AU2955597A (en) Substituted phenyluracils
AU2987097A (en) De-wiring apparatus